Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Biotechnology

Healthcare
$162.86 -0.45%

-$0.71 today

Market cap
$16.48B
Beta
0.40
P/E (TTM)
23.8
EPS (TTM)
$6.65
52W Low $122.14High $169.57

Volume 1.60M

Average 1.18M

NBIX Inventory

Raw materials, work in progress, and finished goods held for sale.

Neurocrine Biosciences, Inc.NASDAQ: NBIX

Inventory · Q3 FY2026 · quarter ended Sep 2026

Inventory falls 4.6% from a year ago

Inventory stood at $66.1M at the end of Q3 FY2026, down 4.6% from a year earlier and down 36.6% from the prior quarter. Over 3 fiscal years it compounded at +25.3% a year.

Context

  • Inventory amounted to 1.2% of total assets at the end of Q3 FY2026, down 0.4 pp from a year earlier.
  • Inventory increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether inventory keeps falling in the next quarterly balance sheet after a -4.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$66.1M-36.6% QoQ
Last fiscal yearDec 2025
$69M+20.2% YoY
Year agoSep 2025
$69.3M-4.6% since
Inventory past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.6%——
1 year+20.2%——
3-year CAGR+25.3%——
5-year CAGR——
10-year CAGR——

Inventory history

USD · from the balance sheet

Latest · FY2025
69M USD
Year-over-year change
+20.2%
4-year CAGR
+22.6%

Inventory vs competitors

How NBIX compares with its peers on the latest reported figures

  • NBIX's Sep 2026 inventory of $66.1M is the 3rd highest of the 10 companies compared; the peer median is $1.7M.
  • Its year-over-year change of -4.6% is the 4th highest of 6, against a peer median of +38.7%.
  • Inventory amounts to 1.2% of total assets for NBIX, versus a peer median of 0.4%.
NBIX Competitors Peer median
Inventory for NBIX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
JAZZJazz Pharmaceuticals plcSep 2026$454M -6.0%-16.4%3.8%
SUPNSupernus Pharmaceuticals, Inc.Jun 2026$83.92M +90.6%-3.5%5.9%
NBIXNeurocrine Biosciences, Inc.Sep 2026$66.1M -4.6%+25.3%1.2%
ACADACADIA Pharmaceuticals Inc.Sep 2026$40.36M +38.7%+73.5%2.2%
AXSMAxsome Therapeutics, Inc.Jun 2026$37.88M +105.4%+86.3%5.0%
VNDAVanda Pharmaceuticals Inc.Mar 2026$1.7M -11.6%+15.8%0.4%
BHVNBiohaven Ltd.Jun 2026$0 ——0.0%
GHRSGH Research PLCMar 2026$0 ——0.0%
RAPPRapport Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
Peer median (excluding NBIX) $1.7M+38.7%+15.8%0.4%

Competitors are the stored peer set for NBIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents340.8M262.9M251.1M233M713M
Short-term Investments370.5M726.4M780.5M843.1M767.4M
Net Receivables185.5M350M439.3M479.1M686.8M
Inventory30.5M35.1M38.3M57.4M69M
Other Current Assets45.5M79.1M97.8M63.6M115.8M
Total Current Assets972.8M1.45B1.61B1.72B2.52B
Property, Plant & Equipment (Net)155.8M145.6M347.3M592M545.2M
Goodwill00000
Intangible Assets037.2M35.5M36.5M0
Long-term Investments624.4M401.5M849.4M864.3M1.18B
Tax Assets315.1M305.9M362.6M485.7M320.3M
Other Non-current Assets4.4M25M49.6M15.5M59.5M
Total Non-current Assets1.1B915.2M1.64B1.99B2.11B
Total Assets2.07B2.37B3.25B3.72B4.63B
Account Payables51.5M67.3M133.3M99.9M104.9M
Short-term Debt0169.4M170.1M00
Tax Payables09M24.4M00
Deferred Revenue00000
Other Current Liabilities133.3M225.4M261.4M297.8M423.9M
Total Current Liabilities245.8M537.7M654.8M507.7M743.4M
Long-term Debt335.1M0000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities12.3M29.7M106.3M166.2M219.7M
Total Non-current Liabilities452.7M123.2M364.6M621.3M635M
Total Liabilities698.5M660.9M1.02B1.13B1.38B
Common Stock100K100K100K100K100K
Retained Earnings(635.8M)(406.8M)(157.1M)29.2M447.7M
Accumulated OCI(1.7M)(7.9M)7M5.8M13.1M
Other Stockholders Equity00000
Minority Interest00000
Total Equity1.37B1.71B2.23B2.59B3.25B
Total Debt440.4M262.9M428.4M455.1M415.3M
Net Debt99.6M0177.3M222.1M(297.7M)

Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Intrinsic Alpha fair value

Locked

Current Price

$162.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.